2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 4
1
Phase 2
1
Status
Completed
5
Sponsor Class
INDUSTRY
4
OTHER
1
Study Type
Interventional
4
Observational
1
Sponsor
Cancer Type
Endocrine
5
Breast
3
Conditions
Breast Neoplasms
326
Neoplasm Metastasis
40
Neoplasms
25
Ovarian Neoplasms
18
Advanced Breast Cancer
18
Carcinoma, Non-Small-Cell Lung
14
Endometrial Neoplasms
11
Prostatic Neoplasms
10
Hereditary Sensory and Autonomic Neuropathies
10
Triple Negative Breast Neoplasms
8
Colorectal Neoplasms
6
Breast Cancer Metastatic
6
Uterine Cervical Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Recurrence
5
Multiple Endocrine Neoplasia Type 1
5
Carcinoma, Ovarian Epithelial
5
Breast Diseases
5
Neoplasms by Site
4
Stomach Neoplasms
3
Small Cell Lung Carcinoma
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Fallopian Tube Neoplasms
3
Carcinoma, Lobular
3
Breast Neoplasm Female
3
Uterine Neoplasms
2
Pancreatic Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Interventions
Fulvestrant
5
Exercise
5
Eating
5
Standard of Care
3
Sodium Chloride
3
Diet
3
Alpelisib
3
ribociclib
2
gallium Ga 68 dotatate
2
exemestane
2
Vitamin D
2
Tamoxifen
2
Magnetic Resonance Spectroscopy
2
Letrozole
2
Ethanol
2
Blood Specimen Collection
2
Anastrozole
2
zopiclone
1
ziprasidone
1
veliparib
1
testosterone undecanoate
1
testosterone enanthate
1
pazopanib
1
mirabegron
1
methyl hydroxyethyl cellulose
1
lenvatinib
1
fluorocholine
1
evolocumab
1
dimethandrolone-undecanoate
1
cyclopropapyrroloindole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
5 trials
Recent
Start date
Enrollment
Multiple Endocrine Neoplasia Type 1
×
Fulvestrant
×
Clear all
NCT05631795
2026-04-07
ALPINIST
Novartis
Phase 4
Completed
40 enrolled
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled
NCT02437318
2025-02-13
SOLAR-1
Novartis
Phase 3
Completed
572 enrolled
22 charts
1 FDA
NCT02422615
2023-11-30
MONALEESA-3
Novartis
Phase 3
Completed
726 enrolled
17 charts
1 FDA
NCT02753686
2023-02-15
Treat ER+ight
Novartis
Completed
440 enrolled